Your browser is no longer supported. Please, upgrade your browser.
Settings
TRIL [NASD]
Trillium Therapeutics Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own6.39% Shs Outstand103.78M Perf Week-1.46%
Market Cap2.28B Forward P/E- EPS next Y-2.92 Insider Trans-1.67% Shs Float98.89M Perf Month1.16%
Income-60.70M PEG- EPS next Q-0.90 Inst Own76.09% Short Float10.01% Perf Quarter134.58%
Sales0.15M P/S15436.66 EPS this Y53.50% Inst Trans- Short Ratio3.54 Perf Half Y81.72%
Book/sh2.91 P/B6.01 EPS next Y28.10% ROA-16.90% Target Price11.02 Perf Year19.05%
Cash/sh2.51 P/C6.98 EPS next 5Y- ROE-19.20% 52W Range5.80 - 20.96 Perf YTD18.97%
Dividend- P/FCF- EPS past 5Y20.60% ROI-23.40% 52W High-16.51% Beta1.94
Dividend %- Quick Ratio19.80 Sales past 5Y- Gross Margin- 52W Low201.72% ATR0.20
Employees33 Current Ratio19.80 Sales Q/Q- Oper. Margin- RSI (14)62.16 Volatility0.95% 1.13%
OptionableYes Debt/Eq0.00 EPS Q/Q36.10% Profit Margin- Rel Volume0.37 Prev Close17.58
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.80M Price17.50
Recom1.50 SMA20-0.66% SMA5018.20% SMA20052.16% Volume1,044,059 Change-0.46%
Apr-14-21Initiated The Benchmark Company Buy $21
Oct-12-20Initiated Evercore ISI Outperform
Sep-10-20Upgrade H.C. Wainwright Neutral → Buy $16.50
Aug-17-20Initiated Craig Hallum Buy $15
Jun-19-20Initiated Oppenheimer Outperform
May-26-20Initiated JMP Securities Mkt Outperform $10
Apr-13-18Resumed Leerink Partners Mkt Perform $7
Jul-17-17Initiated H.C. Wainwright Buy $7
Aug-03-16Initiated Ladenburg Thalmann Buy $18
May-15-15Initiated Oppenheimer Outperform $32
Apr-27-15Initiated Leerink Partners Outperform $29
Oct-05-21 08:34AM  
Sep-22-21 08:00PM  
Sep-21-21 08:00AM  
Sep-17-21 02:30AM  
Sep-15-21 09:49AM  
Sep-14-21 04:10PM  
Sep-11-21 12:01PM  
06:25AM  
Sep-09-21 11:56AM  
04:32AM  
Sep-08-21 10:15AM  
Sep-07-21 08:00AM  
Sep-04-21 05:55AM  
Sep-03-21 05:15PM  
Sep-01-21 11:47AM  
Aug-30-21 05:37PM  
05:05PM  
05:00PM  
Aug-26-21 04:11PM  
03:53PM  
03:17PM  
12:15PM  
Aug-24-21 07:19PM  
01:00PM  
12:15PM  
12:03PM  
11:10AM  
10:50AM  
09:31AM  
05:11AM  
Aug-23-21 08:05PM  
04:07PM  
03:45PM  
02:44PM  
02:41PM  
12:38PM  
12:14PM  
12:01PM  
11:06AM  
10:51AM  
10:06AM  
09:57AM  
09:47AM  
09:44AM  
09:39AM  
09:08AM  
08:36AM  
07:09AM  
07:04AM  
06:55AM  
06:45AM  
06:21AM  
04:14AM  
02:52AM  
Aug-13-21 07:00AM  
Aug-09-21 07:00AM  
Aug-04-21 06:45AM  
Jul-29-21 09:40AM  
Jul-13-21 08:58AM  
Jul-07-21 05:18AM  
Jul-06-21 07:00AM  
Jun-30-21 07:00AM  
Jun-29-21 07:00AM  
Jun-25-21 06:28PM  
Jun-09-21 07:00AM  
May-07-21 07:00AM  
Apr-28-21 09:11AM  
07:01AM  
07:00AM  
06:20AM  
Apr-22-21 07:00AM  
Apr-08-21 11:25AM  
Apr-06-21 08:30AM  
Apr-01-21 07:31AM  
Mar-25-21 06:10AM  
Mar-18-21 04:05PM  
Feb-01-21 04:32PM  
Jan-29-21 12:00AM  
Jan-25-21 05:35PM  
Jan-24-21 10:30AM  
Jan-13-21 08:09AM  
Jan-12-21 03:51PM  
Jan-05-21 05:21AM  
Jan-04-21 04:45PM  
11:47AM  
10:00AM  
07:33AM  
Dec-21-20 03:15PM  
Dec-17-20 08:52AM  
Dec-16-20 07:57PM  
Dec-15-20 06:35AM  
Dec-11-20 08:42AM  
Dec-09-20 04:02PM  
Dec-08-20 10:25AM  
07:04AM  
Dec-07-20 04:05PM  
08:29AM  
Dec-01-20 05:03PM  
Nov-26-20 07:49AM  
Nov-25-20 07:00AM  
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Uger RobertChief Scientific OfficerJul 07Option Exercise0.303,6461,1083,646Jul 09 04:30 PM
Uger RobertChief Scientific OfficerJul 07Sale9.003,64632,8140Jul 09 04:30 PM
Uger RobertChief Scientific OfficerJun 07Option Exercise0.323,6461,1483,646Jun 09 04:23 PM
Uger RobertChief Scientific OfficerJun 07Sale8.273,64630,1520Jun 09 04:23 PM
Skvarka JanPresident and CEOMay 12Option Exercise0.3123,8027,47423,802May 13 04:12 PM
Skvarka JanPresident and CEOMay 12Sale9.2423,802219,8800May 13 04:12 PM
Skvarka JanPresident and CEOMay 11Option Exercise0.42106,69845,071106,698May 13 04:12 PM
Skvarka JanPresident and CEOMay 11Sale9.20106,698981,8030May 13 04:12 PM
Uger RobertChief Scientific OfficerMay 07Option Exercise0.313,6461,1413,646May 11 04:24 PM
Uger RobertChief Scientific OfficerMay 07Sale9.303,64633,9080May 11 04:24 PM
Petrova PenkaChief Development OfficerApr 08Option Exercise1.805,3129,5785,312Apr 09 05:23 PM
Petrova PenkaChief Development OfficerApr 08Sale11.095,31258,9100Apr 09 05:23 PM
Uger RobertChief Scientific OfficerApr 07Option Exercise0.303,6461,0983,646Apr 09 05:38 PM
Uger RobertChief Scientific OfficerApr 07Sale10.823,64639,4500Apr 09 05:38 PM
Uger RobertChief Scientific OfficerMar 12Option Exercise3.392,9179,8962,917Mar 15 05:12 PM
Uger RobertChief Scientific OfficerMar 12Sale11.972,91734,9160Mar 15 05:12 PM
Petrova PenkaChief Development OfficerMar 10Option Exercise1.805,3129,5455,312Mar 12 04:40 PM
Petrova PenkaChief Development OfficerMar 10Sale11.085,31258,8570Mar 12 04:40 PM
Uger RobertChief Scientific OfficerMar 08Option Exercise0.303,6461,0933,646Mar 10 05:57 PM
Uger RobertChief Scientific OfficerMar 08Sale10.113,64636,8610Mar 10 05:57 PM
Petrova PenkaChief Development OfficerFeb 09Option Exercise9.625084,888508Feb 10 07:18 PM
Uger RobertChief Scientific OfficerFeb 09Option Exercise9.625845,619584Feb 10 07:18 PM
Petrova PenkaChief Development OfficerFeb 09Sale14.175087,2000Feb 10 07:18 PM
Uger RobertChief Scientific OfficerFeb 09Sale14.125848,2480Feb 10 07:18 PM
Uger RobertChief Scientific OfficerFeb 08Option Exercise1.646,56310,7516,563Feb 10 07:18 PM
Petrova PenkaChief Development OfficerFeb 08Option Exercise1.785,3129,4355,312Feb 10 07:18 PM
Uger RobertChief Scientific OfficerFeb 08Sale12.656,56383,0220Feb 10 07:18 PM
Petrova PenkaChief Development OfficerFeb 08Sale12.655,31267,1970Feb 10 07:18 PM
Skvarka JanPresident and CEOJan 14Option Exercise0.4319,5818,37119,581Jan 15 04:19 PM
Skvarka JanPresident and CEOJan 14Sale15.0319,581294,2790Jan 15 04:19 PM
Skvarka JanPresident and CEOJan 13Option Exercise0.425,4192,3025,419Jan 15 04:19 PM
Skvarka JanPresident and CEOJan 13Sale15.045,41981,5080Jan 15 04:19 PM
Petrova PenkaChief Development OfficerJan 11Option Exercise9.575084,860508Jan 13 04:11 PM
Uger RobertChief Scientific OfficerJan 11Option Exercise9.575845,587584Jan 13 04:12 PM
Petrova PenkaChief Development OfficerJan 11Sale15.215087,7250Jan 13 04:11 PM
Uger RobertChief Scientific OfficerJan 11Sale15.205848,8790Jan 13 04:12 PM
Petrova PenkaChief Development OfficerJan 08Option Exercise3.332,6048,6742,604Jan 12 04:10 PM
Uger RobertChief Scientific OfficerJan 08Option Exercise8.388,51771,3655,600Jan 12 04:11 PM
Parsons James T.Chief Financial OfficerJan 08Option Exercise7.248,50561,6168,505Jan 12 04:12 PM
Parsons James T.Chief Financial OfficerJan 08Sale15.798,505134,2710Jan 12 04:12 PM
Uger RobertChief Scientific OfficerJan 08Sale15.718,517133,8060Jan 12 04:11 PM
Petrova PenkaChief Development OfficerJan 08Sale15.502,60440,3650Jan 12 04:10 PM
Petrova PenkaChief Development OfficerJan 07Option Exercise0.302,7088092,708Jan 11 04:19 PM
Uger RobertChief Scientific OfficerJan 07Option Exercise0.303,6461,0893,646Jan 11 04:17 PM
Petrova PenkaChief Development OfficerJan 07Sale14.712,70839,8430Jan 11 04:19 PM
Uger RobertChief Scientific OfficerJan 07Sale14.753,64653,7820Jan 11 04:17 PM